AU784971B2 - Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies - Google Patents

Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies Download PDF

Info

Publication number
AU784971B2
AU784971B2 AU76260/00A AU7626000A AU784971B2 AU 784971 B2 AU784971 B2 AU 784971B2 AU 76260/00 A AU76260/00 A AU 76260/00A AU 7626000 A AU7626000 A AU 7626000A AU 784971 B2 AU784971 B2 AU 784971B2
Authority
AU
Australia
Prior art keywords
antibody
radiolabeled
patient
bone marrow
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU76260/00A
Other languages
English (en)
Other versions
AU7626000A (en
Inventor
William H Rastetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of AU7626000A publication Critical patent/AU7626000A/en
Assigned to BIOGEN IDEC INC. reassignment BIOGEN IDEC INC. Amend patent request/document other than specification (104) Assignors: IDEC PHARMACEUTICALS CORPORATION
Application granted granted Critical
Publication of AU784971B2 publication Critical patent/AU784971B2/en
Assigned to BIOGEN INC. reassignment BIOGEN INC. Request to Amend Deed and Register Assignors: BIOGEN IDEC INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU76260/00A 1999-08-11 2000-07-25 Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies Expired AU784971B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14828799P 1999-08-11 1999-08-11
US60/148287 1999-08-11
PCT/US2000/040459 WO2001010462A1 (en) 1999-08-11 2000-07-25 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Publications (2)

Publication Number Publication Date
AU7626000A AU7626000A (en) 2001-03-05
AU784971B2 true AU784971B2 (en) 2006-08-10

Family

ID=22525101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76260/00A Expired AU784971B2 (en) 1999-08-11 2000-07-25 Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies

Country Status (11)

Country Link
EP (1) EP1207906A4 (no)
JP (1) JP2003513012A (no)
CN (2) CN101259270A (no)
AU (1) AU784971B2 (no)
CA (1) CA2378646A1 (no)
HK (1) HK1048945A1 (no)
MX (1) MXPA02001398A (no)
MY (1) MY136635A (no)
NO (1) NO20020639L (no)
TW (1) TWI279233B (no)
WO (1) WO2001010462A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PT3284753T (pt) 2002-10-17 2020-05-04 Genmab As Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2519870A1 (en) 2003-04-09 2004-10-28 Genentech, Inc. Use of rituximab intravenous compositions to treat rheumatoid arthritis
JP5416338B2 (ja) 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
CA2526402A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
DK2348051T3 (en) 2003-11-05 2019-03-18 Roche Glycart Ag CD20 antibodies with increased fc receptor binding affinity and effector function
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CN106075435A (zh) 2004-06-04 2016-11-09 健泰科生物技术公司 用于治疗多发性硬化的方法
BR122018016031B8 (pt) 2004-08-04 2021-07-27 Applied Molecular Evolution Inc processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
CN101267836A (zh) 2005-07-25 2008-09-17 特鲁比昂药品公司 单剂量cd20特异性结合分子的用途
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
SG10202005450PA (en) 2007-07-09 2020-07-29 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010074724A1 (en) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2639288C2 (ru) 2009-08-11 2017-12-20 Дженентек, Инк. Получение белков в культуральных средах без глутамина
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
EP2536279A4 (en) 2010-02-19 2013-07-24 Millennium Pharm Inc CRYSTALLINE FORMS OF SODIUM 4 - {[9-CHLORO-7- (2-FLUORO-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-D] [2] BENZAZEPHIN-2YL] AMINO} -2-METHOXYBENZOATE
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
EP3247395A1 (en) * 2015-01-23 2017-11-29 Immunomedics, Inc. Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114031689A (zh) 2015-10-02 2022-02-11 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
MX2019003029A (es) * 2016-09-16 2019-09-13 Nordic Nanovector Asa Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano.
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送系统、制备方法及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5843439A (en) * 1992-11-13 1998-12-01 Anderson; Darrell R. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1112084B2 (en) * 1998-08-11 2012-04-25 Biogen Idec Inc. Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843439A (en) * 1992-11-13 1998-12-01 Anderson; Darrell R. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MALONEY ET AL.MONOCHONAL ANTI.ONCOLOGY(1998)VOL12NO.8PP63-76 *

Also Published As

Publication number Publication date
TWI279233B (en) 2007-04-21
JP2003513012A (ja) 2003-04-08
CN1373671A (zh) 2002-10-09
WO2001010462A1 (en) 2001-02-15
CN101259270A (zh) 2008-09-10
CN100389825C (zh) 2008-05-28
EP1207906A4 (en) 2005-07-06
MY136635A (en) 2008-11-28
EP1207906A1 (en) 2002-05-29
AU7626000A (en) 2001-03-05
HK1048945A1 (en) 2003-04-25
NO20020639D0 (no) 2002-02-08
NO20020639L (no) 2002-04-11
MXPA02001398A (es) 2002-08-12
CA2378646A1 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
AU784971B2 (en) Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
EP1131096B1 (en) Anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
JP2019065023A (ja) 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
ES2563439T3 (es) Medios y métodos para tratar LDCBG
Vose et al. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma
CN102133410A (zh) B细胞恶性瘤和自身免疫病的免疫疗法
JP2003506413A (ja) 中間および高グレードの非ホジキンリンパ腫の抗−ｃｄ２０抗体による治療
JP2010285439A (ja) キメラ抗ｃｄ２０抗体を用いた、循環腫瘍細胞に関連した血液学的悪性疾患の治療
MX2007000748A (es) Metodos para tratar el sindrome de sjogren.
US20210163618A1 (en) Chimeric canine anti-cd20 antibody
JP2018533588A (ja) 治療パラダイム
KR20200010472A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
CN111526893A (zh) 减少抗cd30抗体药物偶联物疗法的副作用的方法
US20220347313A1 (en) Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers
CN115611981A (zh) 抗pd-1抗体在治疗外周t细胞淋巴瘤中的应用
AU2005211669B2 (en) Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
NZ722296B2 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: BIOGEN IDEC INC.

Free format text: FORMER NAME: IDEC PHARMACEUTICALS CORPORATION

MK14 Patent ceased section 143(a) (annual fees not paid) or expired